GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

Novartis’ RLT received US FDA approval for earlier use in mCRPC. Credit: Konektus Photo/Shutterstock. Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified ...

Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.

The Phase III trial follows the company’s previous Phase I trial, which saw 12 participants dosed with Bemdaneprocel. Credit: Shutterstock / Yuri A US-based Bayer subsidiary BlueRock Therapeutics has ...

The plan will launch a national standardised contract, simplifying paperwork and eliminating redundant technical assurances. Credit: Nanci Santos Iglesias / Shutterstock. The UK Government has ...

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

Pfizer is working with regulators and Data Monitoring Committee to investigate the cause of the patient’s death. Credit: Alexandros Michailidis/ Shutterstock.com. Pfizer has reported the death of a ...

The pipeline continues to look strong for HIV but the hunt for a cure or vaccine continues. Image credit: Shutterstock / PENpics Studio The year 2023 started with disappointing news for the field of ...

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...

The clinical trial sector reflects on what it believes will be the biggest difficulties of 2025. Image credit: Shutterstock / 3rdtimeluckystudio It has been a turbulent time for the pharmaceutical ...